European Journal of Molecular & Clinical Medicine

Abstract

BACKGROUND: Gestational Diabetes mellitus (GDM) is defined as Glucose
Intolerance, the valuesof plasma glucose falling in the range of Diabetes which is
observed and detected for the first
timeduringsecondorthirdtrimesterofpregnancy.GDMisquite
oftenassociatedwithhighermaternalandneonatalmorbiditiesin theshort andlong-term
andpredisposesbothwomen andchildto laterdevelopment of type 2 Diabetes
OBJECTIVE OF THE STUDY: the objective of our study is
tocomparematernalandneonataloutcomesinGDMpatientswhoareonmetforminandinsulin.
MATERIALS &METHODS: the study on evaluation of metformin versus insulin
therapy in themanagement of gestational diabetes was conducted in dept. of OBG Adesh
Institute of
MedicalSciences,Ambalaafterobtaininginstitutionalethicalcommitteeclearanceforaperiod
ofoneyearfromJanuary 2021 to December 2021 in the age group of 26-35 years.
Maternal and neonatal outcomesrecorded include: maternal: incidence of pre-eclampsia,
PIH, neonatal outcomes include: macrosomia,birth weight, the incidence of small for
gestational age, prematurity, Apgar score at the age of 5 min,hypoglycaemia. We also
compared the mode of delivery (spontaneous, assisted or caesarean section)between the
two groups. RESULTS & CONCLUSIONS: It is quite evident from in our study
thattherewerenostatisticallysignificantdifferencesinboththegroupswithrespecttomaternalc
omplications, mode of delivery and neonatal complications. In our study, we found that
the oral antidiabetic medication metformin is equally effective as insulin in the treatment
of GDM patients andwithout higher risks for maternal or neonatal complications.
However, further randomized clinicalstudies with large number of patients and with
long-term follow-up of children is needed to
determinetheroleofMetforminasanalternativetreatmenttoinsulinin GDMpatients